Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
Public ClinicalTrials.gov record NCT06132035. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Clinical Study to Evaluate the Safety of CG-P5 Peptide Eye Drops (Self-administered and Topically Applied) in Patients Diagnosed With Age-related Wet Macular Degeneration
Study identification
- NCT ID
- NCT06132035
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Caregen Co. Ltd.
- Industry
- Enrollment
- 45 participants
Conditions and interventions
Conditions
Interventions
- CG-P5 peptide Drug
- Placebo Drug
- Aflibercept Injection [Eylea] Drug
Drug
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 21, 2023
- Primary completion
- Apr 30, 2025
- Completion
- Jul 31, 2025
- Last update posted
- Feb 6, 2025
2023 – 2025
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CBCC Global Research Site:005 | Manchester | Connecticut | 06042 | Recruiting |
| CBCC Global Research Site:006 | Deerfield Beach | Florida | 33064 | Recruiting |
| CBCC Global Research Site:001 | Augusta | Georgia | 30909 | Recruiting |
| CBCC Global Research Site:004 | Carmel | Indiana | 46290 | Recruiting |
| CBCC Global Research Site:003 | Fargo | North Dakota | 58104 | Recruiting |
| CBCC Global Research Site:002 | Erie | Pennsylvania | 16507 | Recruiting |
| CBCC Global Research Site:007 | Philadelphia | Pennsylvania | 19141 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06132035, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 6, 2025 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06132035 live on ClinicalTrials.gov.